Nanosurgery in Metastatic Breast Cancer as Postsurgical Adjuvant Treatment,Targeted Nanoimaging, and Immunotargeted Radiation Therapy Enhancement with Nanomedicine

Primary tabs

Acta Medica International,2015,2,2,5-8.
Published:July 2015
Type:Guest Editorial

Nanosurgery in Metastatic Breast Cancer as Postsurgical Adjuvant Treatment,Targeted Nanoimaging, and Immunotargeted Radiation Therapy Enhancement with Nanomedicine

John N Giannios,

President and Chief Medical Editor, Official Journal of Hellenic and International Society of Molecular and Genomic Medicine and Research, President of the International Association of Personalised Peri-operative Medicine and Nanosurgery and Assembly Head of the American Society of Biomedicine. 

Abstract:

Approximately 15-20% of breast Ca consists of triplenegative phenotype/basal-like Ca (BL/Triple(-) BCa) due to a lack of expression in ER, PR and HER-2 oncogene making it an extremely heterogeneous group of cancers that are very aggressive and have been associated with a very poor prognosis.

These tumors are characterized by an enhanced relapse pattern, and potent chemo/radio-resistance due to breast CD44+ CD24- cancer stem cells (BCSCs) which are associated with cell-invasion and metastasis of breast Ca because CD44 is a receptor for hyaluronic acid that interacts with other ligands such as osteopontin which activates PI3K/AKT,HIF-1a and MMP2-9.1 Collagen that activates N-cadherin and c-JunNH(2)-terminal kinase (JNK)2,and MMP 2,9 and 13 which dissolves bone matrix promoting osteolytic bone metastasis by complementing the activity of MMP-9,MT1-MMP and other invasive and metastatic enzymes.Read more.....

Keywords:Nil

John N Giannios